Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)
SPRY Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
76.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
271.40%
SPRY Stock Analysis
SPRY
PE Ratio:
SPRY
PEG Ratio:
Not Available
SPRY
Forward EPS Growth (12 month):
0.00%
SPRY
PS Ratio:
8.8
SPRY
PSG Ratio:
0.1
SPRY
Forward Revenue Growth (12 month):
87.50%
SPRY Articles
No data was found